VHL; Von Hippel-Lindau disease tumor suppressor; Protein G7; pVHL
Applications:
IHC;IF;ELISA
Recommended Dilutions:
Immunohistochemistry: 1/100 - 1/300. ELISA: 1/40000. Not yet tested in other applications.
Immunogen:
The antiserum was produced against synthesized peptide derived from human VHL. AA range:34-83
Storage:
Rabbit
Storage:
-20°C/1 year
Clonality:
Polyclonal
Isotype:
IgG
Concentration:
1 mg/ml
GeneID（Human）:
7428
Human Swiss-Prot No:
P40337
Cellular localization:
[Isoform 1]: Cytoplasm. Membrane; Peripheral membrane protein. Nucleus. Found predominantly in the cytoplasm and with less amounts nuclear or membrane-associated. Colocalizes with ADRB2 at the cell membrane.; [Isoform 3]: Cytoplasm. Nucleus. Equally distributed between the nucleus and the cytoplasm but not membrane-associated.
Background:
von Hippel-Lindau tumor suppressor(VHL) Homo sapiens Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq, Jul 2008],
